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SUMMARY
Immune checkpoint inhibitors have improved patient
survival in melanoma, but the innate resistance of
many patients necessitates the investigation of alter-
native immune targets. Many immune checkpoint
proteins lack proper characterization, including
V-domain Ig suppressor of T cell activation (VISTA).
VISTA expression on immune cells can suppress
T cell activity; however, few studies have investi-
gated its expression and regulation in cancer cells.
In this study, we observe that VISTA is expressed in
melanoma patient samples and cell lines. Tumor
cell-specific expression of VISTA promotes tumor
onset in vivo, associated with increased intratumoral
T regulatory cells, and enhanced PDL-1 expression
on tumor-infiltrating macrophages. VISTA transcript
levels are regulated by the stemness factor Forkhead
box D3 (FOXD3). BRAF inhibition upregulates FOXD3
and reduces VISTA expression. Overall, this study
demonstrates melanoma cell expression of VISTA
and its regulation by FOXD3, contributing to the
rationale for therapeutic strategies that combine tar-
geted inhibitors with immune checkpoint blockade.
INTRODUCTION
Inhibitory immune checkpoint proteins promote cancer growth
by suppressing T cell responses; thus, releasing these check-
points enhances the ability of the immune system to kill cancer
cells. US Food andDrug Administration (FDA) approval of check-
point inhibitors targeting cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4) and programmed cell death 1 (PD-1), such
as ipilimumab, pembrolizumab, and nivolumab, has improved
patient survival and increased response durability in melanoma.
However, objective response rates range from 19% to 58% of
patients (Hodi et al., 2018). Mechanisms of acquired and adap-
tive resistance to immune checkpoint blockade include T cell
dysfunction, melanoma cell dedifferentiation, and upregulation
of compensatory immune checkpoint proteins (Jenkins et al.,
2018; Mehta et al., 2018). As such, additional immune modula-
tory proteins such as LAG-3, TIM-3, and TIGIT are under inves-
tigation in clinical trials for their potential as therapeutic targets in
melanoma (clinical trials: NCT03470922, NCT02817633, and
NCT02913313). Targeting multiple immune checkpoints is syn-
ergistic, suggesting that checkpoint proteins may engage in
distinct, non-redundant activities (Nirschl and Drake, 2013).
Hence, the specific role of each immune checkpoint protein in
modulating the anti-tumor immune response requires further
study.
V-domain immunoglobulin (Ig) suppressor of T cell activation
(VISTA) has been identified as a putative immune checkpoint
protein that inhibits T cell activation and proliferation (Le Mercier
et al., 2014; Wang et al., 2011). VISTA is primarily expressed on
hematopoietic cells and only a few studies have evaluated its
expression on cancer cells (Villarroel-Espindola et al., 2018;
Wang et al., 2011). The role of VISTA is controversial. Some
studies propose that VISTA acts as a ligand expressed on anti-
gen-presenting cells to inhibit T cells (Le Mercier et al., 2014;
Wang et al., 2011), while other studies suggest that it behaves
as an inhibitory receptor on T cells (Flies et al., 2014). Moreover,
VISTA has been linked to the phagocytic clearance of cancer
cells (Yoon et al., 2015) and the regulation of MT1-MMP for
cancer cell invasion (Sakr et al., 2010). Thus, VISTA modulation
of the tumor immune microenvironment remains unclear, and
its precise role in cancer requires further characterization. In
melanoma, VISTA expression on antigen-presenting cells
promotes tumor growth independently of PD-1/PD-L1 (Liu
et al., 2015), and it is upregulated on tumor-infiltrating macro-
phages after ipilimumab treatment (Gao et al., 2017). These
studies suggest that VISTA can behave in a compensatory
mechanism when another immune checkpoint is blocked.
VISTA has also been implicated in embryogenesis, playing
a critical role in bone morphogenetic protein 4 (BMP4)-depen-
dent differentiation of mouse embryonic stem cells and
the temporal regulation of stemness markers (Aloia et al.,
2010). These wide-ranging studies highlight a potential,
unusual connection between immune modulatory and stemness
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Figure 1. VISTA Is Expressed in Patient Samples and Correlates with T Cell Dysfunction
(A and B) Survival analysis was performed on TCGA’s cutaneous melanoma dataset using non-recurrent stage III patients with a regional lymph, cutaneous, or
subcutaneous tumor sample (n = 186). Patients were stratified by VISTA RNA-seq expression (high = Z score > 1) and by expression-based estimation of
cytotoxic lymphocyte (CTL) level (combined expression of CD8A, CD8B,GZMA,GZMB, and PRF1). Shown are Kaplan-Meier curves using overall survival times
from date of biospecimen accession for patients with low versus high CTL, concurrent with (A) low or (B) high VISTA levels. The 10-year restricted mean survival
times (RMSTs) were calculated for each cohort.
(C) The T cell dysfunction score for VISTA was calculated in melanoma using the tumor immune dysfunction and exclusion (TIDE) computational framework.
VISTA was found to be significantly synergistic with T cell dysfunction.
(D) Whole pieces of human tumor samples were homogenized, lysed, and probed for VISTA expression by western blot. B, BRAF mutant; N, NRAS mutant; WT,
BRAF/NRAS wild type. ACTIN was used as a loading control.
(E) Patient tumor sampleswere stainedwith fluorescent antibodies for flow cytometry analysis. Cells were gated for CD45 positivity to select for immune cells, and
the VISTA expression level was determined and analyzed in this subset compared to negative controls and expression in other cell subsets in the same sample.
(legend continued on next page)
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pathways. In melanoma, stemness and dedifferentiation are
associated with resistance to targeted therapy and immune
checkpoint blockade (Mehta et al., 2018; Tsoi et al., 2018). Tar-
geting agents against VISTA have entered clinical trials (e.g.,
NCT02812875); however, a thorough understanding of the role
of VISTA in cancer and, specifically, in melanoma is lacking.
Forkhead box D3 (FOXD3) is a transcription factor known for
its role in neural crest cell differentiation, with the potential
to act as both an initiator and a repressor of transcription (Krish-
nakumar et al., 2016). Our lab previously demonstrated that
FOXD3 is upregulated in response to BRAF inhibitors and medi-
ates adaptive resistance to therapy in melanoma (Abel et al.,
2013). Targeted inhibition of BRAF can enhance immune cell
infiltration into melanoma tumors (Wilmott et al., 2012). The
extent to which FOXD3 regulates targets that may alter the
anti-tumor immune response remains unknown. In the present
study, we evaluated the tumor-specific expression of VISTA
in melanoma. We observed that VISTA promotes tumor onset
in immunocompetent mouse melanoma models and that the
mutant BRAF-regulated transcription factor, FOXD3, sup-
presses VISTA expression at the transcript level. Overall, we
provided insight into the role of tumor-specific VISTA expression
and identified a regulatory connection between FOXD3 and
VISTA.
RESULTS
VISTA Expression Is Associated with T Cell Dysfunction
in Melanoma
Several studies suggest that VISTA behaves as an inhibitory im-
mune checkpoint protein; however, its precise role requires
further characterization. In melanoma, we evaluated VISTA as-
sociation with T cell dysfunction using a workflow that was pre-
viously generated for the determination of anti-tumor immune
response regulators (Jiang et al., 2018). We performed survival
analysis on The Cancer Genome Atlas (TCGA) cutaneous mela-
noma dataset of non-recurrent stage III patients with a regional
lymph, cutaneous, or subcutaneous tumor sample (n = 186)
(Broad Institute TCGA Genome Data Analysis Center, 2016).
These 186 samples were stratified by low versus high VISTA
RNA sequencing (RNA-seq) expression (The Cancer Genome
Atlas Network, 2015). Since tumor-infiltrating lymphocytes
(TILs) and cytolytic activity are associated with improved survival
in melanoma (The Cancer Genome Atlas Network, 2015), sam-
ples were further classified by cytotoxic lymphocyte (CTL) level
(sum of CD8A, CD8B, GZMA, GZMB, and PRF1 expression)
and survival time from date of biospecimen accession was
plotted for each expression group. In patients who expressed
low levels of VISTA, there was a statistically significant decrease
in survival in the lowCTL versus the highCTL cohort (4.07 years
versus 8.75 years for 10-year restricted mean survival time
[RMST]; Figure 1A). Conversely, when patients exhibited high
levels of VISTA, the difference in survival between the low and
high CTL cohorts was no longer evident (5.40 years versus
5.02 years RMST; Figure 1B). VISTA expression was also asso-
ciated with a positive Z score of interaction with
T cell dysfunction when analyzed within the tumor immune
dysfunction and exclusion (TIDE) Cox proportional hazards
model (Figure 1C) (Jiang et al., 2018). These data suggest that
high VISTA expression is associated with decreased CTL func-
tion and that in melanoma patients with low VISTA expression,
high CTL is associated with improved survival.
Next, we analyzed VISTA expression in melanoma patient
samples obtained from surgeries (Table S1). By western blotting
of whole-tumor samples, we observed varying levels of VISTA
expression (Figure 1D). Since these samples contained multiple
cell types, we analyzed the specific expression of VISTA on
immune cells by flow cytometry. Tumor-associated immune
cells, defined by CD45 positivity, displayed a range of VISTA
positivity (39.5%–75.7%) (Figures 1E, S1A, and S1B). We
analyzed RNA-seq datasets from the melanoma TCGA to further
assess immune cell-specific expression of VISTA. Each patient
sample in the melanoma TCGA is annotated with an Lscore,
the sum of lymphocyte distribution and lymphocyte density
determined by immunohistochemistry. We observed that VISTA
expression was significantly elevated in samples with high
Lscores (Figure 1F). We still observed high levels of VISTA
expression in samples that showed no evidence of lymphocyte
infiltration (Lscore = 0) or low levels of lymphocyte infiltration
(Lscore = 2) (Figure 1F). These findings indicate that VISTA is
expressed in patient samples but that its expression may not
be exclusive to immune cells.
VISTA Is Expressed on Melanoma Cells
To determine whether VISTA is specifically expressed on mel-
anoma cells, we analyzed patient samples by flow cytometry.
VISTA expression was observed with a range of 14.9%–57%
on CD45S100+/Melan-A+/GP100+ melanoma cells (Figures
2A, S1A, and S1B). VISTA expression was further analyzed
by immunohistochemistry (IHC), and tumor-specific staining
was determined by a pathologist. High tumor-specific positiv-
ity was observed in 4 of 13 samples, moderate/low positivity
was observed in 8 of 13 samples, and 1 of 13 samples was
negative (Figure 2B; Table S1). A tumor microarray of stage
III and stage IV melanoma patient samples was analyzed for
VISTA expression by IHC and tumor cell-specific expression
of VISTA was again detected. When scored by a pathologist
in a blinded manner and normalized to the number of nuclei
in each sample, the levels of tumor cells expressing VISTA
ranged from 0%–5.9% (Figure 2C). No significant difference
was observed in tumor-specific VISTA expression between tu-
mor types, mutation statuses, stages, or sexes (Figures S1C–
S1F). We also observed VISTA expression in monocultures of
melanoma cell lines analyzed by western blot (Figure 2D). The
(F) Melanoma IHC samples from TCGA were previously scored for lymphocyte density and lymphocyte distribution. These two scores were summed to give an
Lscore (no samples had an Lscore of 1). Samples were categorized by Lscore, and VISTA expression was analyzed in each category. Lscores > 3 demonstrate a
statistically significant enhancement of VISTA expression; however, VISTA expression is still easily detectable in samples determined to have no or few immune
infiltrates (Lscore = 0, 2). *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S1 and Table S1.
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Figure 2. VISTA Is Expressed in Melanoma Patient Samples and Cell Lines
(A) Patient tumor samples were stained with fluorescent antibodies for flow cytometry analysis. Cells were gated for CD45 negativity, then gated for S100/
MELANA/GP100 positivity to select for melanoma cells. The VISTA expression level in this subset was determined by comparing fluorescence levels to negative
controls and to other cell subsets in the same sample.
(B) IHC staining for VISTA was performed on melanoma patient samples. Tumor cell-specific membranous VISTA staining was judged by a pathologist, and the
expression level was defined as high, 15%–65% VISTA+ tumor cells; moderate/low, 1%–14%; negative, 0%. Representative samples were imaged at 403
magnification; scale bars, 50 mm.
(C) IHC staining for VISTA was performed on a tissue microarray (TMA) of melanoma patient samples. Tumor cell-specific membranous VISTA staining was
scored by a pathologist, and the number of large nuclei was counted using Visiopharm software. The number of tumor-positive VISTA cells was divided by total
nuclei for each sample, and the number of patients showing a range of tumor-specific VISTA expression was plotted. Representative samples were imaged at
403 magnification; scale bars, 50 mm.
(legend continued on next page)
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reagents used to detect VISTA by western blot were validated
by small interfering RNA (siRNA) knockdown of VISTA (Fig-
ure 2E). VISTA showed a complex banding pattern and inhibi-
tion of N-linked glycosylation led to a dramatic band shift (Fig-
ures S2A and S2B), indicating that VISTA is post-
translationally modified by glycosylation. VISTA expression
was analyzed in other cell types and found to be low or unde-
tectable on melanocytes, but highly expressed on keratino-
cytes, fibroblasts, and some cancer-associated fibroblast
(CAF)-like cells (Capparelli et al., 2015, 2018) (Figure S1G).
These data demonstrate that VISTA is expressed on multiple
cell types in the tumor microenvironment.
Melanoma-Specific VISTA Expression Promotes Tumor
Onset
We tested the role of VISTA expression on melanoma cells in an
immunocompetent setting. Themousemelanoma cell line, D4M,
was mutagenized by UVB irradiation to create UV2 cells with
increased neoantigen expression. The endogenous expression
of VISTA was undetectable to low in vitro and in vivo in D4M
UV2 cells; thus, we engineered cells to overexpress VISTA (Fig-
ures 3A, 3B, and S3A). VISTA overexpression did not alter cell
growth in in vitro IncuCyte assays (Figure 3C). Furthermore,
VISTA knockdown in human melanoma cells had little effect on
in vitro cell proliferation, 2-dimensional (2D) wound healing, or
3-dimensional (3D) invasion (Figures S2C–S2G).
VISTA may exert tumor-extrinsic effects on the immune
microenvironment. To determine VISTA effects in vivo, D4M
UV2 cells were injected intradermally into C57BL/6 mice and
tumor growth was monitored. We observed that tumor-spe-
cific VISTA expression in D4M UV2 led to faster time-to-tumor
onset, defined as reaching a tumor volume of 50 mm3
(Figures 3D and S3B). Similar effects were observed in another
UV-mutagenized mouse melanoma cell line, YUMM1.7,
engineered to express VISTA (Figures 3F and S3C-S3E)
(Wang et al., 2017). In contrast, tumor-specific VISTA expres-
sion had no effect on tumor onset in immunodeficient NSG
mice (Figures 3E and 3G). Furthermore, tumor-specific
expression of VISTA in the poorly immunogenic parental cell
lines D4M and YUMM1.7 had no effect on time-to-tumor onset
(Figures S3F–S3H). Although we observed significant effects
on tumor growth at early time points, tumor cell-specific VISTA
had little effect on long-term tumor growth and survival
(Figures S3I and S3J). These data suggest that VISTA expres-
sion in melanoma cells promotes tumor onset in immunocom-
petent models.
VISTA-Expressing Tumors Have Alterations in TIL
Populations and Respond to Immune Checkpoint
Blockade
To assess the effects of melanoma-specific VISTA expression
on TILs in vivo, we harvested D4M UV2 and D4M UV2 VISTA
tumors after 7 days and analyzed TILs by flow cytometry. In
VISTA-expressing tumors, we observed an increase in the per-
centage of immunosuppressive T regulatory cells (Tregs;
FOXP3+CD4+CD3+CD45+) compared to tumors from parental
cells (Figure 4A). No differences were detected in the infiltration
or activation potential of CD8+ or CD4+ T cells (Figures S4A–
S4F). Furthermore, VISTA expression on mouse melanoma cells
did not alter T cell killing in in vitro cytotoxicity assays (Figures
S4J and S4K).
Next, we evaluated effects on innate immune cell populations
and observed a decrease in major histocompatibility complex
(MHC) class II levels, quantified by mean fluorescence intensity,
on dendritic cells (DCs; F4/80CD11c+MHCIIhiCD3CD45+),
suggesting that these antigen-presenting cells are less activated
(Figures 4B and S4I). Comparable numbers of tumor-associated
macrophages (TAMs; CD11b+F4/80+CD3CD45+) and myeloid-
derived suppressor cells (MDSCs; CD11b+GR-1+CD3CD45+)
were isolated from D4M UV2 tumors and D4M UV2 VISTA tu-
mors (Figures S4G and S4H); however, TAMs and MDSCs
from D4M UV2 VISTA tumors expressed increased cell surface
levels of PD-L1 (Figures 4C and 4D). Since PD-L1-expressing
macrophages are important targets of PD-1/PD-L1 blockade
(Lin et al., 2018), we tested whether animals bearing D4M UV2
VISTA tumors could benefit from therapeutic targeting of the
PD-1/PD-L1 immune checkpoint axis. Treatment with a PD-1
blocking antibody (RMP1-14) led to a growth delay of
12.2 days on average compared with isotype control (95% con-
fidence interval [CI]: 6.5–17.8; p = 0.001) and to improved sur-
vival (Figures 4E and S5E). Compared to mice with parental tu-
mors, mice with VISTA-expressing tumors experienced a trend
toward decreased survival under anti-PD-1 treatment, although
this effect did not reach statistical significance (Figures S5A–
S5D).
Next, we tested the efficacy of a VISTA-blocking antibody
(clone 13F3) in D4M UV2 VISTA-expressing tumors. Within
the control treatment group, 6 of 7 mice progressed rapidly;
however, in the anti-VISTA antibody treatment group, we
observed a highly heterogeneous response (Figure 4F). Only
2 of 8 mice treated with anti-VISTA antibody showed rapid tu-
mor progression, while the remaining 6 mice treated with anti-
VISTA antibody showed a delayed response, and 2 tumors ul-
timately progressed (Figure 4F). The heterogeneity of
response precluded statistical analysis using standard tumor
growth curve models; however, anti-VISTA treatment
increased median tumor volume doubling time from 7 to
29 days, resulting in a hazard ratio of 2.84 (90% CI: 1.02–
7.95, p = 0.095) (Figure 4G). In addition, there was a trend to-
ward increased survival with anti-VISTA treatment, but this
was not statistically significant (Figure S5F). We conclude
that VISTA expression in tumors promotes an increase in
several immunosuppressive cell populations and phenotypes.
Furthermore, these tumors still respond to anti-PD-1 therapy,
which is consistent with VISTA being independent of the PD-1/
PD-L1 immune checkpoint axis (Liu et al., 2015).
(D) A panel of lysates frommelanoma cell lines was probed for VISTA expression by western blot. An empty lane was eliminated, denoted by the solid black line.
(E) Cells were transfected with a non-targeting control siRNA or siRNA against VISTA for 72 h. Cells were lysed and protein expression was probed by
western blot.
See also Figures S1 and S2 and Table S1.
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The Transcription Factor FOXD3 Regulates VISTA
Levels in Melanoma Cells
VISTA plays roles in both the immune system and embryogen-
esis as a critical component of BMP4-mediated signaling (Aloia
et al., 2010). In melanoma cells, VISTA knockdown did not
alter BMP4 downstream signaling, as measured by levels of
phospho-SMAD1/5 and expression of ID2 (Figures S6A and
S6B). Next, we asked whether VISTA is regulated by embryonic
pathways in melanoma. FOXD3 regulates the melanocytic
switch during neural crest cell differentiation and is upregulated
in response to BRAF inhibition (Abel et al., 2013; Weiss et al.,
2014). In the pan-cancer TCGA dataset, FOXD3 was highly
Figure 3. Tumor-Specific Expression of VISTA Promotes Tumor Onset
(A) The mouse melanoma cell line, D4M UV2, was engineered to express a V5-tagged VISTA, and expression was verified by western blot.
(B) As for (A), except that expression was verified by flow cytometry.
(C) In vitro cell growth of D4M UV2 cells expressing VISTA was evaluated using the IncuCyte live cell imager. No significant difference in cell growth was found.
Data are representative of 3 independent experiments.
(D) Cells were injected into C57BL/6mice, and tumorsweremeasuredby caliper every 2–3 days. Tumorswere considered fully formedwhen they reached~50mm3,
at which point it was considered the time of tumor onset. Data were collected from a total of 18 mice per group from 2 independent experiments. *p < 0.05.
(E) Cells were injected into NSG mice and time-to-tumor onset was tracked, as in (D). Data were collected from a total of 5 mice per group.
(F) YUMM1.7 cells were engineered and injected as in (A). Tumorswere considered fully formedwhen they reached ~50mm3. Data were collected from a total of 6
mice per group from 2 independent experiments. *p < 0.05.
(G) Cells were injected into NSG mice and time-to-tumor onset was tracked, as in (F). Data were collected from a total of 5 mice per group.
See also Figures S2 and S3.
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Figure 4. VISTA Expression Promotes an Immunosuppressive Microenvironment, but Does Not Alter Response to PD-1
(A) Tumors were analyzed for tumor-infiltrating lymphocytes 7 days after injection. The presence of FOXP3+CD4+CD3+ T regulatory cells was determined by flow
cytometry as a percentage of cells gated as Live and CD45+. Data were collected from 9 mice per group, combined from 2 independent experiments. *p < 0.05.
(B) As in (A), dendritic cells (gated as Live F4/80CD11c+MHCIIhiCD3CD45+) were analyzed for MHC II levels by flow cytometry, andmean fluorescence intensity
(MFI) was quantified. *p < 0.05.
(legend continued on next page)
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expressed in melanoma compared to other cancers (Figure 5A)
(Cerami et al., 2012; Gao et al., 2013). We reevaluated a
microarray dataset from A375 cells induced to express either
FOXD3 or LacZ (control) (Abel et al., 2013). FOXD3 selectively
downregulated the expression of VISTA, but did not alter the
expression of other immune modulatory proteins (Figure 5B).
Furthermore, expression of FOXD3, but not LacZ, was sufficient
to reduce the total cellular expression and cell surface levels of
VISTA (Figures 5C–5E, and S6D). Reagents used to detect VISTA
by flow cytometry were validated by siRNA knockdown
(Figure S6D).
PD-L1 and indoleamine 2,3-dioxygenase 1 (IDO1) were unde-
tectable at basal levels, but they were induced following inter-
feron g (IFNg) treatment. These immunomodulatory proteins
were minimally downregulated or unaltered by FOXD3 expres-
sion (Figures 5C and S6C). Analysis of the TCGA RNA-seq
data showed a significant positive correlation between VISTA
and PD-L1 (Figure S6E). Furthermore, using flow cytometry,
we detected the co-expression of VISTA and PD- L1 on mela-
noma cells and the co-expression of VISTA and PD-1 on immune
cells in a patient tumor sample (Figure S6F). While PD-L1 is an
IFNg-stimulated protein, VISTA levels were unaltered by treat-
ment with IFNg, as well as by treatment with other cytokines
and growth factors (Figures 5C, S6G, and S6H). Analysis
across a panel of mutant BRAF melanoma cell lines showed
that VISTA levels are inversely correlated with basal levels of
FOXD3 (Figure 5F). These data identify an unusual connection
between the stemness factor FOXD3 and VISTA in melanoma
cells.
FOXD3 Regulates VISTA Transcript Levels
To determine how FOXD3 regulates VISTA expression, we
introduced two point mutations, N187A and H191A, that
are known to ablate the DNA-binding capabilities of FOXD3
(Yaklichkin et al., 2007). While the expression of wild-type
FOXD3 reduced VISTA levels, the DNA-binding mutant
FOXD3 N187/H191A had no effect on VISTA expression (Fig-
ures 6A and 6B). Alternatively, mutations that disrupt FOXD3
interaction with Groucho proteins for transcriptional repression
(F378E) (Yaklichkin et al., 2007) or prevent the phosphorylation
of FOXD3 at serine site 46 (S46A) (Figure S7A) did not interfere
with FOXD3-mediated repression of VISTA (Figure S7B). These
data demonstrated that FOXD3 regulation of VISTA is depen-
dent on its DNA-binding domain. Furthermore, FOXD3 expres-
sion reduced VISTA transcript levels by qRT-PCR (Figures 6C
and S7D). Reagents to detect VISTA expression by qRT-PCR
were validated using siRNA knockdown (Figure S7C). VISTA
protein was not altered by proteasome or autophagy inhibitors
(Figures S7E and S7F), indicating that protein stability and auto-
phagy are not predominant regulators of VISTA protein levels.
These findings indicate that FOXD3 regulates VISTA transcript
levels.
Next, we reevaluated a chromatin immunoprecipitation
sequencing (ChIP-seq) dataset of FOXD3 expression (Abel
et al., 2013). We observed three putative FOXD3 binding peaks
associated with intron 1 of the VSIR gene encoding VISTA (Fig-
ure 6D). Next, we performed ChIP assays in A375 cells inducibly
expressing V5-FOXD3 to verify FOXD3 binding at these peaks.
Using primers designed to be specific to each peak, we
observed V5-FOXD3 binding at peaks 1 and 2 (Figure 6E; Table
S2). ChIP specificity in these samples was confirmed by FOXD3
binding to a known target,ERBB3 (Abel et al., 2013) (Figure S7G).
These findings show that FOXD3 reduces VISTA transcript levels
and directly binds intron 1 of the VSIR gene.
BRAF Inhibition Reduces VISTA Protein and Transcript
Levels
FOXD3 is upregulated in response to BRAF inhibitors (Abel et al.,
2013). Since FOXD3 suppresses VISTA expression in melanoma
cells, we predicted that pharmacological inhibition of mutant
BRAFwould also affect VISTA levels. PLX4720 is the non-clinical
tool compound of the FDA-approved BRAF inhibitor vemurafe-
nib, and the effects of these compounds are indistinguishable
(Bollag et al., 2010; Joseph et al., 2010; Tsai et al., 2008). Mutant
BRAF melanoma cells were treated with PLX4720 to inhibit
BRAF signaling, as evidenced by reduced levels of phospho-
MEK and phospho-ERK1/2 (Figure 7A). PLX4720 treatment
reduced VISTA protein and transcript levels over time, as de-
tected by western blot and qRT-PCR, respectively (Figures 7A
and 7C). The combination of BRAF and MEK inhibitors is FDA
approved for the treatment of BRAF V600E/K melanoma (Larkin
et al., 2014). We treated mutant BRAF melanoma cells with a
combination of PLX4720 and the MEK inhibitor PD0325901
and detected a reduction in VISTA expression over time
(C) As in (A), tumor-associated macrophages (TAMs) (gated as Live CD11b+F4/80+CD3CD45+) were analyzed for PD-L1 positivity. MFI of PD-L1+ cells was
quantified in the TAM immune cell population. **p < 0.01.
(D) As in (A), myeloid-derived suppressor cells (MDSCs) (gated as Live CD11b+GR-1+CD3CD45+) were analyzed for PD-L1 positivity. MFI of PD-L1+ cells was
quantified in the MDSC immune cell population. *p < 0.05.
(E) D4M UV2 VISTA cells were injected into C57BL/6 mice. When tumors reached ~50 mm3, animals were treated with either anti-PD-1 antibody or the corre-
sponding isotype control (rat IgG2a) every 2–3 days. Data were collected from 5 mice treated with isotype and 6 mice treated with anti-PD-1. One animal in the
anti-PD-1 treatment group with zero tumor volume was excluded from the statistical analyses of tumor growth curves. For the remaining animals, the fitted group
average tumor growth curves are depicted by a bold line. Anti-PD-1 treatment delayed tumor growth on average by 12.2 days (95% CI 6.5–17.8, p = 0.001) as
compared to the control group.
(F) D4M UV2 VISTA cells were injected into C57BL/6 mice. When tumors reached ~50 mm3, animals were treated with either anti-VISTA antibody or the cor-
responding isotype control (hamster polyclonal IgG) every 2–3 days. Data were collected from 7 mice treated with isotype and 8 mice treated with anti-VISTA.
(G) The time to doubling was defined as the first observation daywhen the tumor volume exceeded twice the volume at day 0. Animals with tumor volumes that did
not double at any time were censored on the last day of observation. The time to doubling was analyzed using the Kaplan-Meier estimator of the survival curves
and Cox proportional hazards model.
See also Figures S4 and S5.
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(Figure 7B). BRAF knockdown by siRNA also reduced VISTA
transcript levels (Figure 7D). These data demonstrated that
BRAF inhibition reduces the expression of VISTA at the tran-
script level. We treated a short-term culture of the human
BRAF V600E mutant melanoma patient sample TJUMEL54
with the combination of PLX4720 and PD0325901. BRAF and
MEK inhibition led to the upregulation of FOXD3 and the down-
regulation of VISTA (Figure 7E). Western blot detection of VISTA
in TJUMEL54 was verified by siRNA knockdown of VISTA in a
short-term culture (Figure 7F). These data demonstrate that
BRAF inhibition upregulates FOXD3 and suppresses the
expression of VISTA.
DISCUSSION
The role of VISTA in cancer requires further characterization.
Furthermore, the melanoma cell-specific expression and regu-
lation of VISTA have not been investigated. In this study, we
observed that VISTA was expressed on melanoma cells in pa-
tient samples and cell lines, and its tumor-specific expression
promoted tumor onset in immunocompetent mouse models.
VISTA expression was regulated by FOXD3, and the targeted
inhibition of BRAF signaling reduced VISTA transcript levels.
Thus, we show melanoma cell expression of this immune
checkpoint protein and identify mechanisms regulating its
expression.
In the melanoma TCGA dataset, patients with immune-rich
tumors showed longer survival in the low VISTA subset, and
this effect was lost in high VISTA expressers. Survival time is re-
ported from the date of diagnosis. Since many samples were
procured long after diagnosis, analyses ofmolecular data on sur-
vival should be interpreted with caution (Liu et al., 2018). None-
theless, an overall trend showed that survival times were altered
by CTL and VISTA expression levels. A novel aspect of our work
is the identification of VISTA expression on melanoma cells.
We observed a range of VISTA expression in patient samples
and noted that even low levels of positivity can be meaningful.
By comparison, PD-L1 positivity is defined by a cutoff of 1%–
5% tumor cell staining (Weber et al., 2013). Immune checkpoint
expression on diverse cell populations within the tumor can have
distinct influences on the anti-tumor immune response. In head
and neck cancer and adult T cell leukemia/lymphoma, high
PD-L1 expression in immune cells and stromal cells, respec-
tively, is a favorable prognostic factor, while high PD-L1 expres-
sion in tumor cells trends toward a negative prognostic factor
(Kim et al., 2016; Miyoshi et al., 2016). Thus, tumor-specific
VISTA expression can have important implications for its role in
melanoma.
VISTA has been detected on non-melanoma cancer cells (Mu-
lati et al., 2019; Villarroel-Espindola et al., 2018), and its expres-
sion in tumor cells may have significant implications for its role in
cancer. For example, VISTA expression on ovarian and endome-
trial cancer cells can suppress T cell proliferation, infiltration,
and cytokine production (Mulati et al., 2019). We observed that
VISTA expression on melanoma cells did not inhibit T cell killing
in vitro. In light of a recent study that shows that VISTA effects on
T cells may be pH dependent, the examination of additional
experimental conditions may be required to see the full range
of VISTA effects (Johnston et al., 2019). In the present study,
we demonstrated that melanoma cell-specific expression of
VISTA promoted tumor onset in vivo. VISTA-expressing tumors
showed a decrease in DC activation potential and an increase
in FOXP3+ Tregs, which is consistent with studies that show
that VISTA promotes the induction and maintenance of Treg
pools (Le Mercier et al., 2014). Furthermore, TAMs and MDSCs
in VISTA-expressing tumors showed increased PD-L1 expres-
sion, which could contribute to a more immunosuppressive tu-
mor microenvironment (Gibbons Johnson and Dong, 2017).
The interaction between various immune cell types within the tu-
mormicroenvironment is highly complex. Macrophages can pro-
mote intratumoral Tregs and Tregs can suppress DC-mediated
anti-tumor immunity (Curiel et al., 2004; Jang et al., 2017; Sun
et al., 2017); thus, the mechanism of VISTA effects on tumor
onset may involve effects on multiple cell types. We observed
that tumor-specific expression of VISTA had little effect on
long-term tumor growth. This observation may be explained by
its ability to promote tumor cell phagocytosis (Yoon et al.,
2015) and further highlights the potential complexity of the role
of VISTA on cancer cells and the need to target multiple immune
checkpoints for disease control (Nirschl and Drake, 2013).
VISTA-expressing tumors still respond to PD-1 blockade, indi-
cating that the immune inhibitory effects of VISTA are not strong
enough to outweigh the influence of PD-1/PD-L1 in naive tumors.
Furthermore, since VISTA and PD-L1 are differentially regulated
by IFNg, VISTA expression or targeting is unlikely to be affected
by defects in IFNg signaling associated with resistance to im-
mune checkpoint blockade (Gao et al., 2016). Our observation
that the response to VISTA inhibition is heterogeneous, along-
side the work of others showing that VISTA and PD-1 act inde-
pendently (Liu et al., 2015), further suggests that the combined
targeting of VISTA and PD-1 may show enhanced efficacy
compared to single agent alone.
Figure 5. FOXD3 Is Highly Expressed in Melanoma and Represses VISTA Expression
(A) RNA-seq data from TCGA was analyzed for FOXD3 expression across all of the cancer studies.
(B) Microarray data were reevaluated for FOXD3 regulation of immune checkpoint proteins.
(C) Expression of a V5-tagged FOXD3 was induced by treatment with doxycycline (100 ng/mL). After 48 h, doxycycline was refreshed and IFNg (100 ng/mL) was
added to select wells for an additional 48 h. Cells were lysed and protein expression was probed by western blot. Data are representative of 3 independent
experiments.
(D) Expression of a V5-tagged LacZ control was induced by treatment with doxycycline for 96 h. Cells were lysed and protein expression was probed by western
blot. Data are representative of 3 independent experiments.
(E) FOXD3 expression was induced by treatment with doxycycline for 96 h, and the cell surface levels of VISTA were analyzed by flow cytometry. Shown is the
MFI. Data are representative of 3 independent experiments. *p < 0.05.
(F) A panel of lysates from various melanoma cell lines was probed for the expression of endogenous levels of VISTA and FOXD3 by western blot.
See also Figure S6.
Cell Reports 30, 510–524, January 14, 2020 519
In the present study, we identified VISTA as a FOXD3 gene
target in melanoma cells. We previously discovered that
ERBB3 and TWIST1 are direct targets of FOXD3 in melanoma,
and the FOXD3-binding pattern at the VSIR locus was consis-
tent with FOXD3 binding at intron 1 of the genes encoding
ERBB3 and TWIST1 (Abel et al., 2013;Weiss et al., 2014). During
embryogenesis, FOXD3 represses melanomagenesis in neural
crest cells during a critical lineage switch to neural/glial precur-
sors (Weiss et al., 2014). Studies in mouse embryonic stem cells
and epiblast cells identified a FOXD3 binding peak near the
VSIR gene (Krishnakumar et al., 2016). Whether FOXD3 also
regulates VISTA expression during embryonic development
Figure 6. FOXD3 Regulates Transcription of
VISTA mRNA
(A) A375 cells were treatedwith doxycycline for 96 h
to induce the overexpression of a DNA-binding
mutant FOXD3. VISTA and FOXD3 levels were de-
tected by western blot. Data are representative of 3
independent experiments.
(B) A375 cells were treated with doxycycline for
various lengths of time to induce the expression of
either WT or DNA-binding mutant FOXD3.
(C) Cells were treated with doxycycline for varying
lengths of time to induce FOXD3 expression.
RNA was isolated and qPCR was performed using
2 different Taqman assay probes for VISTA
mRNA. Data are representative of 3 independent
experiments. *p < 0.05, **p < 0.01.
(D) ChIP-seq data of V5-FOXD3 were mined for
FOXD3 binding peaks. Shown is a map of the locus
for the VISTA gene VSIR and aligned reads. Data
were visualized in the Integrated Genomics Viewer.
(E) FOXD3 binding at identified peaks was verified
by ChIP. A375TR/V5-FOXD3 cells were treatedwith
doxycycline for 48 h to induce V5-FOXD3 expres-
sion. V5 antibody was used to pull down FOXD3
protein, and specific primers (Table S2) were used
to probe binding at each peak (labeled in 5D) by
qRT-PCR. Data are representative of 3 independent
experiments. *p < 0.05, **p < 0.01.
See also Figure S7 and Table S2.
requires further investigation. Various
mechanisms are used to protect devel-
oping cells from the maternal immune
system, including the altered expression
of MHC antigen-presenting proteins and
the upregulation of immune-inhibitory
proteins such as IDO1 and PD-L1 (D’Ad-
dio et al., 2011; Trowsdale and Betz,
2006). Our data provide additional con-
nections between transcription factors
involved in embryonic development and
immunomodulatory proteins. Dedifferen-
tiation is a common mechanism of resis-
tance to both targeted therapy and immu-
notherapy in melanoma (Mehta et al.,
2018; Tsoi et al., 2018). This phenomenon
may be explained in part due to the inter-
section between stemness transcription
factors and modulation of immune privilege during embryonic
development.
We observed that mutant BRAF inhibition led to the upregu-
lation of FOXD3 and downregulation of VISTA transcript and
protein levels. BRAF inhibitors enhance immune cell infiltration
into the tumor (Wilmott et al., 2012); however, the effect of
FOXD3 upregulation on the tumor immune microenvironment
has not yet been studied. Our observations that BRAF inhibition
and subsequent FOXD3 upregulation decrease VISTA levels at
the transcript level suggest that therapeutic targeting of the
BRAF pathway will reduce tumor expression of VISTA. It is
not uncommon for oncogenic signaling pathways to regulate
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Figure 7. BRAF Inhibition Suppresses VISTA Expression
(A) Cells were treated with the BRAF inhibitor PLX4720 (1 mM) for the indicated lengths of time. Cell lysates were analyzed by western blot. Shown is a repre-
sentative set of blots from 3 independent experiments.
(B) Cells were treated with a combination of the BRAF inhibitor PLX4720 (1 mM) and the MEK inhibitor PD0325901 (35 nM) for the indicated lengths of time. Cell
lysates were analyzed by western blot. Shown is a representative set of blots from 3 independent experiments.
(C) Cells were treated as in (A) and RNA was isolated. qPCR was performed using 2 independent Taqman probes for VISTA mRNA. Data are representative of 3
independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001.
(legend continued on next page)
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the expression of immune checkpoints; for example, the
expression of PD-L1 can be regulated by signaling downstream
of RAS, epidermal growth factor receptor (EGFR), cyclin depen-
dent kinase 5 (CDK5), and rac family small GTPase 1 (RAC1)
(Coelho et al., 2017; Dorand et al., 2016; Li et al., 2018; Vu
et al., 2015). Studies in melanoma and other cancers show a
similar modulation of the immune checkpoint protein PD-L1
following treatment with therapeutic agents, including inhibitors
of vascular endothelial growth factor receptor 2 (VEGFR2),
BRD/BET proteins, MEK, and phosphatidylinositol 3-kinase
(PI3K) (Hogg et al., 2017; Jiang et al., 2013; Zheng et al.,
2018). These data contribute to the rationale for therapeutic
strategies combining targeted therapies with immune check-
point blockade (Vanneman and Dranoff, 2012). Targeting
agents against VISTA have entered clinical trials, and our
findings further define the cell types that may be affected by
its therapeutic targeting.
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Antibodies
VISTA Cell Signaling Technology Cat# 64953; RRID:AB_2799671
p-ERK1/2 T202/T204 Cell Signaling Technology Cat# 9101; RRID:AB_331646
HSP90 Cell Signaling Technology Cat# 4877; RRID:AB_2233307
PD-L1 Cell Signaling Technology Cat# 13684; RRID:AB_2687655
PD-L2 Cell Signaling Technology Cat# 82723; RRID:AB_2799999
IDO1 Cell Signaling Technology Cat# 86630; RRID:AB_2636818
V5 Cell Signaling Technology Cat# 13202; RRID:AB_2687461
BRAF V600E Spring Bioscience Cat# E19290; RRID:AB_11203850
ACTIN Sigma Cat# A5316; RRID:AB_476743
FOXD3 BioLegend Cat# 631702; RRID:AB_2105424
VISTA Abcam Cat# Ab214933; RRID:AB_2313773
PD-1 BioLegend Cat# 329736; RRID:AB_2629582
S100 Abcam Cat# ab76749; RRID:AB_1566703
GP100 Abcam Cat# Ab137078; RRID:AB_2732921
MART-1 Abcam Cat# ab51061; RRID:AB_880693
CD45.2 BioLegend Cat# 109832; RRID:AB_2565511
FOXP3 Thermo Cat# 14-5773-82; RRID:AB_467576
CD4 BioLegend Cat# 116004; AB_313689
CD3 BioLegend Cat# 100216; RRID:AB_493697
PD-L1 BioLegend Cat# 124321; RRID:AB_2563635
CD11b BioLegend Cat# 101259; RRID:AB_2566568
F4/80 BioLegend Cat# 123116; RRID:AB_893481
GR-1 BioLegend Cat# 108406; RRID:AB_313371
IFNg BioLegend Cat# 505810; RRID:AB_315404
TNFa BioLegend Cat# 506333; RRID:AB_2562450
CD8a BioLegend Cat# 100742; RRID:AB_2563056
CD11c BioLegend Cat# 117308; RRID:AB_313777
I-A/I-E BioLegend Cat# 107630; RRID:AB_2069376
Anti-mouse PD-1 BioXcell Cat# BE0146; RRID:AB_10949053
Rat IgG2a isotype control BioXcell Cat# BE0089; RRID:AB_1107769
Anti-mouse VISTA BioXcell Cat# BE0310; RRID:AB_2736990
Armenian Hamster IgG isotype control BioXcell Cat# BE0091; AB_1107773
Biological Samples
Patient tumor samples Thomas Jefferson University Surgery
Department
TJUMELXXX
Patient Short Term Culture Thomas Jefferson University Surgery
Department
TJUMEL54
Tumor microarray MD Anderson Surgery Department N/A
Chemicals, Peptides, and Recombinant Proteins
PLX4720, BRAF inhibitor Selleck Chemicals PLX4720
PD0325901, MEK inhibitor Selleck Chemicals PD0325901
DharmaFECT Duo Transfection Reagent Dharmacon Inc. #T-2010-01
CellTrace CSFE ThermoFisher C34554
500x Cell Stimulation Cocktail eBioscience #00-4970-03
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BD Cytofix/cytoperm kit BE Biosciences #554714
FoxP3/Transcription factor buffer staining set ebioscience #00-5523-00
BMP4 R&D Systems 314-BP-010
IFNg R&D Systems 285-IF-100
IL-2 BioLegend 714604
OVA peptide (257-264) Genemed Synthesis Inc. Custom order
18S rRNA Taqman Probe ThermoFisher Assay ID Hs99999901_s1
GAPDH Taqman Probe ThermoFisher Assay ID Hs02786624_g1
VISTA Taqman Probe #1 ThermoFisher Assay ID Hs00735289_m1
VISTA Taqman Probe #2 ThermoFisher Assay ID Hs00735287_m1
iQ SYBR Green Supermix Bio-Rad N/A
Critical Commercial Assays
FITC fast conjugation kit Abcam N/A
RNeasy Plant Mini Kit QIAGEN N/A
iScript cDNA Synthesis Kit Bio-Rad N/A
Experimental Models: Cell Lines
Human: A375 BRAF V600E Melanoma Cell line ATCC A375
Human: 1205Lu Melanoma Cell Line The Wistar Institute 1205Lu
Human: WM35 Melanoma Cell Line The Wistar Institute WM35
Mouse: D4M3.A BRAF V600E Melanoma Cell Line Dartmouth University D4M3.A
Mouse: YUMM1.7 BRAF V600E Melanoma Cell Line Yale University YUMM1.7
Mouse: D4M UV2 BRAF V600E Melanoma Cell Line-
mutagenized
Mass General Hospital, Harvard
Medical School
D4M UV2
Mouse: YUMMER1.7 BRAF V600E Melanoma Cell Line-
mutagenized
Yale University YUMMER1.7
Experimental Models: Organisms/Strains
Mouse: C57BL/6 Mice Jackson Labs C57BL/6
Mouse: NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ Jackson Labs then bred at Thomas
Jefferson University
NSG
Mouse: C57BL/6-Tg(TcraTcrb)1100Mjb/J Jackson Labs then bred at Thomas
Jefferson University
OT-1
Oligonucleotides
VISTA siRNA #1 Dharmacon Inc. D-032651-02-0005
VISTA siRNA #2 Dharmacon Inc. D-032651-04-0005
Non-targeting CTL siRNA Dharmacon Inc. D-001810-01
Primers for ChIP, See Table S1 This paper N/A
Recombinant DNA
pLenti4/TO/V5-mVISTA Generated by S. Rosenbaum N/A
pLenti4/TO/V5-FOXD3 Generated by E. Abel N/A
pLenti4/TO/EGFP-FOXD3 Generated by E. Abel N/A
pLenti4/TO/EGFP-FOXD3 N187A/H191A Generated by E. Abel N/A
pLenti4/TO/EGFP-FOXD3 S46A Generated by E. Abel N/A
pLenti4/TO/EGFP-FOXD3 F378E Generated by E. Abel N/A
Software and Algorithms
FlowJo FlowJo, LLC N/A
Quantity One BioRad, Hercules, CA N/A
Graphpad Prism GraphPad N/A
Integrated Genome Viewer (IGV 2.3) program Broad Institute N/A
MyiQ version 1.0 software Bio-Rad N/A
R project N/A http://www.R-project.org
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LEAD CONTACT AND MATERIALS AVAILABILITY
All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agree-
ment. All requests should be directed to and will be fulfilled by the Lead Contact, Andrew Aplin (Andrew.Aplin@jefferson.edu).
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Cell lines
A375 cells (purchased fromATCC in 2005) were cultured in DMEMwith 10%FBS.WM35 and 1205Lu cells (donated by Dr. Meenhard
Herlyn, Wistar Institute, Philadelphia, PA in 2005) were cultured in MCDB153 with 2% FBS, 20% Leibowitz L-15 medium, and 5 mg/
mL insulin. D4M3.A cells (donated by Dr. Constance Brinckerhoff and Dr. David Mullins, Geisel School of Medicine at Dartmouth,
Hanover, NH; 2016) (Jenkins et al., 2014), and D4M UV2 (generated at Mass General Hospital) were cultured in Advanced DMEM
with 10% FBS and 1% L-glut. YUMM1.7 and YUMMER1.7 (donated by Dr. Marcus Bosenberg, Yale School of Medicine; 2014
and 2017, respectively) were cultured in DMEM/F12 with 10% FBS and 1% non-essential amino acids. All cells were maintained
at 37C in 5% CO2. Human cell lines were authenticated by sequencing at NRAS and BRAF loci and by STR analysis.
Animals
6-8 week old male C57BL/6 mice were purchased from Jackson Laboratories. Only male C57BL/6 mice were used because the
melanoma cell lines in this study were originally derived from male mice, which could generate an immune reaction when injected
into immunocompetent female mice. Male and female NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice and C57BL/6-Tg(TcraTcrb)
1100Mjb/J (OT-1) mice were originally purchased from Jackson Laboratories and bred at Thomas Jefferson University. Animals
were randomly assigned to experimental groups, or evenly distributed between sexes for NSG experiments. All animal experiments
were approved by the IACUC (protocol #1052) and performed in a facility at Thomas Jefferson University accredited by the Associ-
ation for the Assessment and Accreditation of Laboratory Animal Care (AAALAC).
Patient samples
20 tumor samples from 17 patients were collected from surgeries performed by Dr. Adam Berger at Thomas Jefferson University
under an Institutional Review Board approved protocol that included written informed consent and was in accordance with recog-
nized ethical guidelines. 8 patients were male, and 9 patients were female. Patients ranged in age from 36 to 84 years old. 8 patients
harbored BRAF mutations, 6 patients harbored NRAS mutations, and 3 patients were wild-type for BRAF and wild-type for NRAS.
Detailed information on these samples is provided in Table S1. Tissue microarrays (TMA) of Stage III and Stage IV patients were
generated at The University of Texas MD Anderson Cancer Center containing 676 tumor samples from 317 patients; samples
were collected from 4 patients at both stage III and stage IV and were considered separately. Of the samples collected, 250 samples
were from 95 stage III patients and 426 samples were from 226 stage IV patients. 95 patients were identified as female, while 226
patients were identified as male. Patients ranged in age from 25 to 110 years old. 116 patients harbored BRAFmutations, 34 patients
harbored NRAS mutations, 129 patients were wild-type BRAF/ wild-type NRAS, and 42 patients had no reported mutation data.
Tumor types included samples of acral melanoma from 19 patients, cutaneous melanoma from 99 patients, lentigo melanoma
from 5 patients, mucosal melanoma from 4 patients, and nodular melanoma from 29 patients.
METHOD DETAILS
In vivo studies
Cells were injected intradermally onto the backs of C57BL/6 or NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice. Cell numbers were
based on previous publications and past experiments (D4M UV2 = 1x106 cells; D4M = 3x105 cells; YUMMER1.7 = 5x105 cells;
YUMM1.7 = 3x105 cells) (Jenkins et al., 2014; Wang et al., 2017). Tumors were considered fully formed when they reached
50mm3. For immune checkpoint blockade experiments, animals began treatment when tumors reached 50mm3 and received
250 mg anti-PD-1 antibody (RMP1-14) or the corresponding isotype control (Rat IgG2a clone 2A3), or 300 mg anti-VISTA antibody
(13F3) or the corresponding isotype control (polyclonal Armenian hamster IgG) (BioXCell; West Lebanon, NH) administered by intra-
peritoneal injection every 2-3 days. Treatments were determined based on previous publications (LeMercier et al., 2014; Wang et al.,
2017). Animals were sacrificed when tumors exceeded 750mm3.
Inhibitors, growth factors, and reagents
Recombinant IFNg and BMP4 were purchased from R&D Systems (Minneapolis, MN). PLX4720 and PD0325901 were purchased
from Selleck Chemicals (Houston, TX).
Immunohistochemical analysis
TJUMEL samples were fixed in formalin, paraffin-embedded, and stained manually. After deparaffinization with xylene, rehydration
with ethanol, and antigen retrieval with Citra Plus 1x, samples were stained with 1:200 anti-VISTA antibody from Cell Signaling
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Technology (D1L2G). The intensity of staining and percentage of positive cells were evaluated by Dr. Peter McCue in a blinded
manner. Expression level was defined as: high, > 15% VISTA+ tumor cells; moderate/low, 1%–14%; negative, 0%. Entire areas
of staining were analyzed. The Ventana Ultraview Benchmark was used for automated staining of the tumor microarray, with
1:100 anti-VISTA antibody from Cell Signaling Technology (D1L2G). The number of positive tumor cells was determined by Dr. Peter
McCue and medical resident Dr. Mehri Mollaee in a blinded manner. The number of large, rounded cell nuclei in each sample was
quantified by Dr. Zhijiu Zhong utilizing Visiopharm software, and VISTA-positive tumor cells were normalized to the number of nuclei
in each sample. The normalized value calculated for each sample was averaged across all samples from the same patient.
Lentiviral construction and transduction
A375TR and 1205LuTR FOXD3 and LacZ cells were previously engineered (Abel and Aplin, 2010). Transgene expression was
induced with doxycycline (100ng/mL). Mouse VISTA was amplified from a Vsir (NM_028732) expression plasmid (OriGene; Rockville,
MD), cloned into pENTR/D-TOPO (Invitrogen; Carlsbad, CA), and LR recombined into pLenti-4/TO/V5-DEST. Expression constructs
and packaging plasmids pLP1, pLP2, pLP/VSVG were cotransfected into HEK293FT cells to generate viral particles. Cells were
transduced with particles for 48 hours and then selected with zeocin, as previously described (Abel and Aplin, 2010).
Western blot analysis
Protein lysates were prepared in Laemmli sample buffer, separated by SDS-PAGE, and proteins transferred to PVDF membranes.
Immunoreactivity was detected using horseradish peroxidase-conjugated secondary antibodies (CalBioTech; Spring Valley, CA)
and chemiluminescence substrate (ThermoScientific; Waltham, MA) on a Versadoc Imaging System (Bio-Rad; Hercules, CA). For
detection of human VISTA (#D1L2G), p-ERK1/2 T202/T204 (#9101), HSP90 (#C45G5), PD-L1 (#E1L3N), PD-L2 (#D7U8C), IDO1
(#D5J4E), and V5 (#D3H8Q) antibodies were purchased from Cell Signaling Technology (Danver, MA). BRAF V600E (VE1) antibody
was purchased from Spring Bioscience (Pleasanton, CA). ACTIN (A2066) antibody was purchased from Sigma (St. Louis, MO).
FOXD3 antibody (#631702) was purchased from BioLegend (San Diego, CA). Mouse VISTA antibody (#Ab214933) was purchased
from Abcam (Cambridge, United Kingdom).
siRNA transfection
Cells were transfected for 4 hours with chemically synthesized siRNA at a final concentration of 25nmol/L using Lipofectamine RNAi-
MAX (Invitrogen) transfection reagent. Cells were harvested after 72 hours of knockdown. Target sequences used were as follows:
Non-targeting control (UGGUUUACAUGUCGACUAA), VISTA #1 (GAUGUGACCUUCUACAAGA), VISTA #2 (GUGCCUGCAUCG
UAGGAAU), BRAF #1 (ACAGAGACCUCAAGAGUAAUU), BRAF #2 (CCGAGACAGUCUAAAGAAAUU) siRNAs were purchased
from Dharmacon (Lafayette, CO).
Flow cytometry
Cells were treated with doxycycline for 96 hours to induce FOXD3 expression, fixed in formalin/BSA/PBS, and then stained with
1 mg/mL of either VISTA antibody (Cell Signaling Technology #D1L2G) or rabbit IgG (Calbiochem) for 1 hour. Next, cells were stained
with Alexa Fluor 647 anti-rabbit secondary antibody (Molecular Probes; Eugene, OR) at 1:750 dilution for 30 minutes. For human
patient samples and mouse tumors, tumor pieces were minced with the gentleMACSTM Octo Dissociator using C Tubes (Miltenyi
Biotec; Bergisch Gladback, Germany) in digestion media (1x HBSS, 0.1mg/ml Collagenase IA, 60 U/ml DNase I) and incubated at
37C for 30 minutes with continuous rotation. Cells were washed with medium (RPMI 1640 with L-glutamine, 10% FBS, 1% Pen-
Strep, and 5x105 b-mercaptoethanol), filtered through a 70mm nylon filter, fixed in formalin/BSA/PBS, and then incubated with
Zombie Fixable Viability Dye (BioLegend) for 10 mins. For human samples, cells were then stained for 1 hour with fluorochrome-con-
jugated antibodies. To identify melanoma cells, live CD45- cells were evaluated for expression of a cocktail of S100, GP100, and
MART-1 antibodies (Cho et al., 2015; Weinstein et al., 2014). Antibodies used for these analyses included: CD45 (BioLegend
#2D1), VISTA (Cell signaling Technology #D1L2G), PD-1 (BioLegend #NAT105), PD-L1 (BioLegend #29E.2A3), S100 (Abcam
#ab76749), GP100 (Abcam #ab137078), MART-1 (Abcam #ab51061). FITC was conjugated to GP100 and MART-1 antibodies using
the FITC fast conjugation kit (Abcam). Cells were analyzed on an LSR II, BD Celesta, or Fortessa flow cytometer (BD Biosciences;
Franklin Lakes, NJ) using Flowjo software (TreeStar, Ashaland, OR). For TIL analysis of mouse tumors, after live/dead stain, cells
were stained for 30 mins with fluorochrome-conjugated antibodies. For Treg staining, cells were fixed and nuclear permeabilized
using the eBioscienceTM FOXP3/Transcription factor buffer staining set and an antibody specific for FOXP3 (clone FJK-16 s)
following company instructions. For T cell re-stimulation assays, cytokine production by T cells was assessed after ex vivo stimulation
with the eBioscienceTM cell stimulation cocktail 500X. Cells were incubated in TCM for 5 hours at 37C in 5%CO2, with 1x stimulation
cocktail and 1 mg/ml brefeldin A (GolgiPlug; BD Biosciences). Cells were then washed with ice-cold FACS, stained with Zombie UV,
then antibodies specific for surface proteins, and then antibodies specific for intracellular cytokines. Mouse tumors were stained with
a cocktail of antibodies against CD45.2 (Biolegend, clone 104), FOXP3 (Thermo, clone FJK-16 s), CD4 (Biolegend, clone RM4.4), CD3
(Biolegend, clone 17A2), PD-L1 (Biolegend, clone 10F.9G2), CD11b (Biolegend, clone M1/70), F4/80 (Biolegend, clone BM8), GR-1
(Biolegend, clone RB6-8C5), IFNg (Biolegend, clone XMG1.2), TNFa (Biolegend clone MP6-XT22), CD8a (Biolegend, clone 53.6.7),
CD11c (Biolegend, clone N418), I-A/I-E (Biolegend, clone M5/114.15.1).
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Chromatin immunoprecipitation
A375TR/V5-FOXD3 cells were treated with doxycycline to induce FOXD3 expression for 48 hours. Chromatin immunoprecipitation
was performed, as previously described (Abel et al., 2013). V5 (Invitrogen #R960-25) and IgG (Cell Signaling #G3A1) antibodies were
used at a concentration of 5 mg/mL for immunoprecipitation. Purified DNA was analyzed by qPCR using iQ SYBR Green Supermix
(Bio-Rad), 0.8 mMoligonucleotide primers, and 5 mL ChIP product. Primer sequences are detailed in Table S2. Primers were designed
using the Integrated Genome Viewer (IGV 2.3) program to visualize sequences located under peaks of interest, and designed to
amplify 206-212bp within the sequence located under each peak. Primer specificity was confirmed by melt curve analysis. Reaction
conditions were as follows: denaturation at 94C for 30 s, annealing at 50C for 30 s, and elongation at 72C for 30 s, with 50 cycles in
total. PCR was performed on an iCycler with MyiQ version 1.0 software (Bio-Rad).
Quantitative RT-PCR
RNA was extracted using the RNeasy Plant Mini Kit (QIAGEN; Hilden, Germany). Conversion to cDNA was achieved through the
iScript cDNA Synthesis Kit (Bio-Rad). Quantitative RT-PCR was carried out using Taqman probes (ThermoFisherScientific), accord-
ing to the manufacturer’s instructions. Relative fold change was calculated after normalization to GAPDH or 18S rRNA using the
comparative Ct method. Taqman probes used were VISTA#1- AssayID#Hs00735289_m1; VISTA#2- AssayID#Hs00735287_m1;
18S rRNA- AssayID#Hs99999901_s1; and GAPDH- AssayID#Hs02786624_g1.
IncuCyte live cell analysis
Cells were trypsinized and plated onto a 6-well or 96-well plate. For scratch wound assays, the IncuCyteWoundMakerTM was uti-
lized to create a uniform scratch across all wells. Photomicrographs were taken every 2 hours using an Incucyte Live cell imager
(Essen Biosciences; Ann Arbor, MI). Plate confluence and wound closure were measured using IncuCyte software and presented
as percentages.
Spheroid Invasion Assay
siRNA transfection was utilized to knockdown VISTA. Twenty-four hours post transfection, cells were plated onto agarose to form
spheroids. Cells were allowed to form spheroids for 4 days, then placed into 3D collagen matrix and incubated for an additional
2 days. Cells were incubated with calcein to mark live cells, and images were taken. The area of the invasive front was quantified
using ImageJ and normalized to the area of the spheroid.
LC-MS/MS
FOXD3was purified frommelanoma cells, and TiO2-based immobilizedmetal ion affinity chromatography (IMAC) was used to enrich
phosphopeptides. Peptides were run through LC-MS/MS and the doubly charged precursor of m/z = 862.36 was identified as a
phosphorylated DSDAGCDSpPAGPPELR. The phosphorylation site at serine-46 was identified by a neutral loss of H3PO4 from y9
fragment after b-elimination.
T cell cytotoxicity assay
CD8+ T cells were expanded from C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-1) transgenic mouse spleens (CD8+ T cells are specific for
OVA peptide), and activated in vitrowith 1 mg/mL OVA peptide (257-264) (Genemed Synthesis Inc; San Antonio, TX) and 30U/mL IL-2
(BioLegend). IL-2 andmedia were refreshed after 48 hours. D4MTR/VISTA cells were treated with or without doxycycline (100ng/mL)
for 48 hours prior to the assay to induce VISTA expression. 7 days post T cell expansion, cancer cells were pulsed with or without
1 mM OVA peptide (257-264) for 1 hour, and then labeled with high (15 mM) or low (5 mM) concentrations of carboxyfluorescein suc-
cinimidyl ester (CSFE) for 20 minutes to distinguish pulsed versus non-pulsed cells. Pulsed and non-pulsed cancer cells were plated
at a 1:1 ratio. T cell expansion was verified by CD8+ flow cytometry staining, and T cells were incubated with cancer cells at varying
ratios for 24 hours. After 24 hours, cells were analyzed by flow cytometry. Target cancer cells were gated by FSC-A/SSC-A, then the
ratio of CSFEhi to CSFElow cells was evaluated and specific lysis was calculated (% Specific Lysis = [1-(Non-transferred control ratio/
Experimental ratio)] x 100).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistics
For TMA analyses, significance was tested using a non-parametric Mann-Whitney U Test. All other statistical analyses were per-
formed using a two-tailed Student t test. In vitro studies were conducted three independent times; values were averaged and repre-
sentative images are shown. For in vivo studies, survival curves and curves showing % tumor-free mice were analyzed using a Log-
rank (Mantel-Cox) test. For growth delay analysis of the anti-PD-1 experiment, tumor volumes in animals that had actual tumor
growthwere analyzed using a non-linear mixed effectsmodel with the randomeffects of animal in the parameters of the tumor growth
curves. The animal with zero tumor volume at the end of experiment (1 in anti-PD-1 group) was excluded from analyses of the tumor
growth curves. The tumor volumes were modeled as exponential functions of Day. For tumor volume doubling analysis of the anti-
VISTA experiment, the time to doubling was defined as the first observation day when the tumor volume exceeded twice the volume
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at day zero. Animals with tumor volumes not exceeding twice the volume at day zero at any time were censored at the last day of
observation. The time to doubling was analyzed using the Kaplan-Meier estimator of the survival curves and Cox proportional hazard
model. A p value of < 0.05 was considered statistically significant. Significance is denoted by *p < 0.05, **p < 0.01, ***p < 0.001.
TCGA analyses
The Cancer Genome Atlas (TCGA) SKCM RNA sequencing (RNA-seq) V2 RSEM normalized counts data were retrieved from the lat-
est Broad GDAC Firehose data run (doi:10.7908/C11G0KM9) (Broad Institute TCGA Genome Data Analysis Center, 2016). Cuta-
neous melanoma survival outcome data and tumor biospecimen data were collected from the TCGA Pan-Cancer Clinical Data
Resource (TCGA-CDR) repository (Liu et al., 2018) and the TCGA Pan-Cancer Atlas publication page (https://gdc.cancer.gov/
about-data/publications/pancanatlas), respectively. Overall survival times were calculated from date of biospecimen accession. Pa-
tient sample data were refined to only include non-recurrent stage III patients with a regional lymph, cutaneous, or subcutaneous
tumor sample (n = 186). Subsequent analyses on this sample set were based on the TIDE workflow previously generated for deter-
mination of anti-tumor immune response regulators (Jiang et al., 2018). TCGA patients were stratified by VISTA RNA-seq expression
(High = z-score > 1), and further classified by cytotoxic lymphocyte (CTL) level, which was calculated by taking the sum of expression
values for CD8A, CD8B, GZMA, GZMB, and PRF1. Kaplan-Meier survival plots were generated using the survminer package (v0.4.3
https://CRAN.R-project.org/packages/survminer/index). Data analyses were performed in R (v3.5.1 http://www.R-project.org/).
T cell dysfunction score was calculated using the Tumor Immune Dysfunction and Exclusion (TIDE) Cox proportional hazards model
(Jiang et al., 2018). For analysis of lymphocyte levels in TCGA samples, each sample was classified by Lscore. Lscore is equal to
the sum of lymphocyte distribution and lymphocyte density scores determined by sample histology (The Cancer Genome Atlas
Network, 2015).
DATA AND CODE AVAILABILITY
This study did not generate any datasets or code. TCGA data are publicly available from cbioportal.org. The microarray dataset of
A375 cells induced to express either FOXD3 or LacZ (Abel et al., 2013) was previously deposited in the GEO database (GSE43962).
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